Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded). (NEBULAMB)
Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded)
Sponsor: Poitiers University Hospital
This PHASE2 trial investigates Allergic Bronchopulmonary Aspergillosis and is currently completed. Poitiers University Hospital leads this study, which shows 11 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
May 2019 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
▶ Show 6 earlier versions
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Oct 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE2
Status: Enrolling By Invitation → Active Not Recruiting
-
Jul 2017 — Oct 2017 [monthly]
Enrolling By Invitation PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Enrolling By Invitation PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE2
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Poitiers University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .